Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, a…
$39.16+4.76%
报价 2026-11-06
市值
$1.72B
EV
$1.58B
PE (TTM)
–
预期 PE (FY2027)
82.0x
52 周区间距高点 -8.4%
$16.02$42.73
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-09 | 1.1x | 0.42 → 0.69（1.7x） | 56.4 |
| FY+32029-09 | 1.1x | 0.42 → 1.30（3.1x） | 30.1 |
毛利率 44% · TTM 收入 $614M · 基数 EPS 0.42（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AZTAAzenta, Inc. | $1.72B | +4.8% | +4.0% | 44.9% | – | – | 173.6x | |
| SYRESpyre Therapeutics, Inc. | $9.59B | +7.5% | 0.0% | 0% | – | – | – | |
| NEOGNeogen Corporation | $2.57B | +0.7% | +3.6% | 47.4% | – | 31.6x | 54.7x | |
| SDGRSchrödinger, Inc. | $2.23B | +3.6% | -4.3% | 59.3% | – | – | – | |
| ESTAEstablishment Labs Holdings Inc. | $2B | +4.0% | +30.6% | 69.1% | – | – | – | 高增长 |
| KMTSKESTRA MEDICAL TECHNOLOGIES, LTD. | $1.72B | +0.9% | +51.5% | 56.5% | – | – | – | 高增长 |
| TDOCTeladoc Health, Inc. | $1.6B | -6.8% | -4.1% | 68.6% | – | 7.5x | 6.9x | |
| NVCRNovoCure Limited | $1.55B | -2.0% | +12.9% | 77% | – | – | – | |
| STAASTAAR Surgical Company | $1.26B | -5.7% | +31.5% | 74.5% | 275.1x | 29.7x | – | 高增长 |
| 同行中位数 | – | – | +8.3% | 63.9% | 275.1x | 29.7x | 30.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q3 2026 | 2026-03-31 Q2 2026 | 2025-12-31 Q1 2026 | 2025-09-30 Q4 2025 | 2025-06-30 Q3 2025 | 2025-03-31 Q2 2025 | 2024-12-31 Q1 2025 | 2024-09-30 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $161.2M | $144.8M | $148.6M | $159.2M | $143.9M | $143.4M | $147.4M | $150.6M |
| Gross Margin | 44.9% | 42.8% | 42.9% | 45.4% | 47.1% | 45.9% | 46.7% | 45.5% |
| Operating Margin | -2.6% | -10.6% | -3.3% | 1.8% | 1.1% | -5.2% | -2.5% | 4% |
| Net Income | $2.5M | $-160.8M | $-15.4M | $50.9M | $-52.8M | $-40.5M | $-11M | $-6.6M |
| Diluted EPS | 0.05 | -3.49 | -0.34 | 1.02 | -1.15 | -0.88 | -0.29 | -0.1 |
| Operating Cash Flow | $2.8M | $12.2M | $20.8M | $2.2M | $25.8M | $14.4M | $29.8M | $13.7M |